Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring its effectiveness, according to Yale research published in JAMA Network Open.

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

The adjuvanted RSV vaccine combines recombinant RSV glycoprotein F stabilised in the prefusion conformation (RSVPreF3) with ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

An infectious disease expert reveals there's one free thing everyone can do to help prevent getting a cold this winter. Read ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...